Jubilant Ingrevia News and Updates

Name: Latest research reports of Jubilant Ingrevia Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Jubilant Ingrevia Ltd.
Rating: 3
Author: Prabhudas Lilladhar

Keep track of all breaking news on Jubilant Ingrevia from all sources in a single place.

Jubilant Ingrevia Ltd.

24 Dec 2025

750.75

3.37%

Anand Rathi starts coverage on Jubilant Ingrevia with 'Buy'; check target

Business Standard

Anand Rathi expects Jubilant's capex cycle to drive a sharp earnings upturn over FY26-28, with consolidated Ebitda seen growing at around a 22 per cent CAGR

Jubilant Ingrevia Ltd. is trading above all available SMAs

Jubilant Ingrevia Ltd.

28 Oct 2025

750.75

3.37%

What should investors do with Jubilant Ingrevia shares post Q2 results?

Business Standard

In Q2, the company reported a flat growth in profit after tax (PAT) at 69.47 crore in Q2FY26, as compared to 59 crore year-on-year (Y-o-Y), up 18 per cent

Promoters pledged 4.86% of shares in last quarter. Total pledge stands at 7.08% of promoter holdings

Jubilant Ingrevia Ltd.

27 Oct 2025

750.75

3.37%

Jubilant Ingrevia Results Earnings Call for Q2FY26

Conference Call with Jubilant Ingrevia Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.

audio

Jubilant Ingrevia Ltd.

27 Oct 2025

750.75

3.37%

to see Rapid results content

Jubilant Ingrevia Ltd.

31 Jul 2025

750.75

3.37%

to see Rapid results content

Jubilant Ingrevia Ltd.

13 Jun 2025

750.75

3.37%

Broker's call: Jubilant Ingrevia (Hold)

Business Line

PL Capital

Jubilant Ingrevia Ltd. has an average target of 713.00 from 1 broker.

Jubilant Ingrevia Ltd.

12 Jun 2025

750.75

3.37%

Jubilant Ingrevia (JUBLINGR IN) Company Update Risk of...

Hold: Jubilant Ingrevia Ltd.

Target

Prabhudas Lilladhar

Jubilant Ingrevia is one of the leading players in India supplying chemical intermediates to agrochemical innovators for almost 3 decades. The company is now transitioning to become a CDMO player and has already signed 2 contracts for agro CDMO, one of which is worth USD300mn and will start contributing to revenue from Q4FY26. As highlighted in our previous report, 7 more molecules with pyridine chemistry are expected to go off-patent by 2028, thus making Jubilant a good fit to manufacture them. However, unlike...

Jubilant Ingrevia Ltd. has an average target of 713.00 from 1 broker.

Jubilant Ingrevia Ltd.

14 May 2025

750.75

3.37%

Jubilant Ingrevia (JUBLINGR IN) Q4FY25 Result Update Steady...

Hold: Jubilant Ingrevia Ltd.

Target

Prabhudas Lilladhar

In FY25, 25+ products were added in funnel for CDMO business across agrochem, pharma and semi-con sector. Jubilant Ingrevia reported a slight decline in topline during the quarter, primarily due to a 14%YoY drop in revenue from the Chemical Intermediates segment. However, the Specialty chemicals and Nutrition & Health solutions segments posted YoY revenue growth of 2% and 15%, respectively, contributing to a 90bps improvement in overall EBITDAM. Agrochemical sales improved during the quarter, while the pharmaceutical segment saw stable...